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Abstract: We aimed to elucidate the effects of caloric and non-caloric sweeteners on liver lipid
metabolism in rats using in vivo magnetic resonance spectroscopy (MRS) and to determine their roles
in the development of liver steatosis. Wistar rats received normal chow and either normal drinking
water, or solutions containing 13% (w/v) glucose, 13% fructose, or 0.4% aspartame. After 7 weeks,
in vivo hepatic dietary lipid uptake and de novo lipogenesis were assessed with proton-observed,
carbon-13-edited MRS combined with 13C-labeled lipids and 13C-labeled glucose, respectively.
The molecular basis of alterations in hepatic liver metabolism was analyzed in detail ex vivo using
immunoblotting and targeted quantitative proteomics. Both glucose and fructose feeding increased
adiposity, but only fructose induced hepatic lipid accumulation. In vivo MRS showed that this was
not caused by increased hepatic uptake of dietary lipids, but could be attributed to an increase in de
novo lipogenesis. Stimulation of lipogenesis by fructose was confirmed by a strong upregulation of
lipogenic enzymes, which was more potent than with glucose. The non-caloric sweetener aspartame
did not significantly affect liver lipid content or metabolism. In conclusion, liquid fructose more
severely affected liver lipid metabolism in rats than glucose, while aspartame had no effect.
Keywords: obesity; fatty liver disease; hepatic steatosis; carbohydrate; glucose; fructose; aspartame
1. Introduction
In 2013, an estimated 2.1 billion people were overweight or obese compared with 857 million
people in 1980 [1]. The rise in obesity is associated with an increased prevalence of non-alcoholic fatty
liver disease (NAFLD), which can progress into non-alcoholic steatohepatitis (NASH), liver cirrhosis,
and hepatocellular carcinoma [2–4]. The increased consumption of simple carbohydrates has been
identified as one of the contributing factors to the obesity epidemic [5]. Especially the chronic
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consumption of fructose, as opposed to glucose, has been linked to the development of obesity,
insulin resistance, dyslipidemia, and hepatic steatosis [6–10].
Unlike glucose, fructose is mainly metabolized by the liver. The metabolism of fructose to
triose phosphate bypasses phosphofructokinase, a key regulatory step of glycolysis, allowing
unregulated entry of fructose into glycolysis independent of hepatic energy status. This leads to
an excess production of triose phosphates, which serve as precursors for de novo lipogenesis [9,11,12].
Additionally, fructose consumption causes activation of transcription factors regulating de novo
lipogenesis, i.e., sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate-responsive
element-binding protein (ChREBP), resulting in increased expression of lipogenic enzymes such as fatty
acid synthase (FAS) and acetyl-CoA carboxylase (ACC) [9–11,13,14]. ACC catalyzes the conversion
of acetyl-CoA into malonyl-CoA, providing the building blocks for fatty acid synthesis. At the
same time, increased levels of malonyl-CoA as a result of fructose-induced overexpression of ACC
suppresses fatty acid β-oxidation through inhibition of carnitine palmitoyl transferase 1 (CPT1) [15].
In addition, fructose suppresses the oxidation of fatty acids by decreasing the activity of peroxisome
proliferator-activated receptor α (PPARα) [14,16–18]. Thus, the stimulation of de novo lipogenesis and
the inhibition of fatty acid β-oxidation likely contribute to fructose-induced hepatic lipid accumulation.
Moreover, fructose feeding has been shown to increase the intestinal production of apolipoprotein B48
(apoB48) [19–21], which may promote the absorption of dietary lipids from the intestine, resulting
in an increased influx of diet-derived lipids into the liver. However, the relative importance of the
different pathways leading to fructose-induced hepatic lipid accumulation remains unknown.
Non-caloric sweeteners simulate the sweet taste of sugars without the calories and are
of great value in the fight against obesity [22]. Some studies showed beneficial effects of the
consumption of non-caloric sweeteners by inducing weight loss and reducing the risk factors
for metabolic syndrome [23–25]. In contrast, others demonstrated a correlation between the use
of non-caloric sweeteners and weight gain and increased risk of type 2 diabetes and insulin
resistance [26–29]. The most controversial and most used non-caloric sweetener is aspartame (methyl
L-α-aspartyl-L-phenylalaninate). Aspartame consumption has been shown to increase fasting blood
glucose levels and induce glucose intolerance in rats and mice, and these effects have been attributed
to compositional and functional changes in gut microbiota [26,30,31]. However, data on the effects of
aspartame on hepatic lipid metabolism are greatly lacking.
The aim of this study was to investigate the effects of caloric (glucose and fructose) and non-caloric
(aspartame) sweeteners on liver lipid content and metabolism in vivo in rats. We recently developed a
method that combines localized proton-observed, carbon-13-edited magnetic resonance spectroscopy
(1H-[13C] MRS) with the oral administration of 13C-labeled lipids to determine dietary lipid uptake
in vivo [32,33]. Here we introduce a new variant of this approach, in which we administer 13C-labeled
glucose instead of 13C-labeled lipids. In this case, the 13C-labeled liver lipids detected by 1H-[13C] MRS
originate from the conversion of 13C-labeled glucose to 13C-labeled lipids through de novo synthesis.
This novel application of 1H-[13C] MRS with the oral administration of 13C-labeled glucose thus allows
in vivo assessment of the contribution of de novo lipogenesis to hepatic lipid accumulation. In the
present study, we applied both methods, i.e., 1H-[13C] MRS with the administration of 13C-labeled
lipids and 1H-[13C] MRS with the administration of 13C-labeled glucose, to determine in vivo dietary
lipid uptake and de novo lipogenesis, respectively, in the livers of rats receiving either normal drinking
water, or 13% (w/v) glucose, 13% (w/v) fructose, or 0.4% (w/v) aspartame in their drinking water, for a
period of 7 weeks. The molecular basis of alterations in hepatic liver metabolism was analyzed in
detail ex vivo using immunoblotting and targeted quantitative proteomics.
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2. Materials and Methods
2.1. Animals and Diets
Adult male Wistar rats (350 ± 2 g, 10–11 weeks of age, n = 60; Charles River Laboratories,
The Netherlands) were housed in pairs in individually ventilated cages with corn cob bedding and
standard cage enrichment at 20 ◦C and 50% humidity on a 12 h light-dark cycle. All animals received
normal chow (9 energy percent (En%) from fat, 67 En% from carbohydrates, 24 En% from protein;
R/M-H diet, Ssniff Spezialdiäten GmbH, Soest, Germany) for the duration of the study. After one
week of acclimatization, the rats were divided into four groups receiving either normal drinking water
(CON), or 13% (w/v) glucose (GLU), 13% (w/v) fructose (FRUC), or 0.4% (w/v) aspartame (ASP) in
their drinking water. The animals had ad libitum access to food and liquids. Body weight and food and
drink intake were determined weekly. The rats received the diets for a period of 7 weeks, after which
each dietary group was divided into two subgroups: experimental group 1 (n = 9 per diet group) for
MRS measurements to determine dietary lipid uptake and for an oral glucose tolerance test (OGTT),
and experimental group 2 (n = 6 per diet group) for MRS to determine de novo lipogenesis and for
hepatic biochemical analyses. Blood samples were taken from the vena saphena before each MRS
experiment and were collected in paraoxon-coated capillaries to prevent lipolysis. The samples were
centrifuged at 1000× g for 10 min and plasma was frozen in liquid nitrogen and stored at −80 ◦C for
later analysis. All animal experiments were reviewed and approved by the Animal Ethics Committee
of Maastricht University (DEC-UM, Maastricht, The Netherlands; project number: 2013-011; date of
approval: 20 March 2013).
2.2. MRS Experiments
To determine total (12C + 13C) intrahepatocellular lipid (IHCL) content and natural abundance
13C enrichment of IHCL in liver after 7 weeks of diet, all animals (n = 15 per diet group) were subjected
to baseline 1H-[13C] MRS measurements in a fed condition.
Two days later, rats from experimental group 1 received 1.5 g [U-13C] labeled algal lipid mixture
(13C enrichment > 98%; fatty acid composition: 53% palmitic acid, 9% palmitoleic acid, 28% oleic acid,
and 6% linoleic acid; Buchem B.V., Apeldoorn, The Netherlands) per kg body weight by oral gavage.
The following 4 h the rats remained fasted, after which 1H-[13C] MRS experiments were performed to
determine 13C-enriched IHCL concentrations.
Starting on the day after baseline MRS measurements, rats from experimental group 2 were
administered 3.33 g [U-13C6]glucose (13C enrichment >98%; Buchem B.V., Apeldoorn, The Netherlands)
per kg body weight by oral gavage, two times a day for a period of 5 days. The following day, 1H-[13C]
MRS experiments were performed in a fed condition to determine 13C-enriched IHCL concentrations.
After these MRS measurements, animals from experimental group 2 were euthanized by incising the
vena cava inferior, and the median lobe of the liver was excised and stored at −80 ◦C.
1H-[13C] MRS experiments were performed on a 7 T horizontal Bruker MR system (Bruker,
Ettlingen, Germany), as described previously [32]. During the MRS experiments, animals were
anaesthetized using 1.5–2.5% isoflurane (IsoFlo®; Abbott Laboratories Ltd., Maidenhead, Berkshire, UK).
Total (12C + 13C) and 13C-labeled IHCL levels are presented as a percentage of the unsuppressed water
signal measured in the same voxel. The relative 13C enrichment determined at baseline was used to
correct the 13C-enriched IHCL levels after administration of 13C-labeled lipids or glucose for natural
abundance of 13C.
2.3. Oral Glucose Tolerance Test
In experimental group 1, two days after the last MRS measurements, an OGTT was performed
(n = 9 per diet group). After an overnight fast, rats received 1 mg/g body weight glucose orally. Blood
samples were taken from the vena saphena just before and at 15, 30, 45, 60, 90, and 120 min after glucose
administration. Plasma glucose concentration was determined using a HemoCue Glucose 201 RT Analyzer
Nutrients 2017, 9, 476 4 of 19
(HemoCue AB, Ängelholm, Sweden), while plasma insulin concentration was analyzed using the Rat
Insulin ELISA kit (Mercodia, Uppsala, Sweden). Areas under the glucose (AUCg) and insulin (AUCi)
curves were calculated. Directly after the OGTT, animals from experimental group 1 were euthanized by
incising the vena cava inferior, and the median lobe of the liver was excised and stored at −80 ◦C.
2.4. Plasma and Tissue Analyses
Plasma triglyceride (TG) and alanine aminotransferase (ALT) were determined using serum
TG determination kit (Sigma-Aldrich, Zwijndrecht, The Netherlands) and EnzyChrom™ ALT assay
kit (Bio-Connect Diagnostics, Huissen, The Netherlands), respectively, following the manufacturer’s
instructions. Liver malonyl-CoA content was determined as described in [34].
2.5. Determination of Glycogen Content in Liver
A 200-mg snap-frozen liver sample was homogenized in 10 mL of 25 mM citrate solution (pH 4.2)
containing 2.5 g/L NaF and centrifuged at 10,000× g for 8 min to remove debris. Glycogen content in
the supernatant was determined using EnzyChrom™ glycogen assay kit (Bio-Connect Diagnostics,
Huissen, The Netherlands) according to the manufacturer’s instructions.
2.6. Glycolytic Enzyme Activities
Pieces of snap-frozen liver were powdered in liquid nitrogen and 10% (w/v) homogenates were
prepared in ice cold phosphate-buffered saline (PBS), pH 7.4. Homogenates were sonicated for 30 s in
the pulse mode (pulse duration 1 s, interval between the pulses 1 s, amplitude 20%) on ice, followed by
10 min centrifugation at 1000× g, 4 ◦C. The supernatant was used for spectrophotometric determination
of enzyme activities of phosphoglucose-isomerase [35], phosphoglycerate kinase [36], and pyruvate
kinase [37]. Protein concentrations in the supernatants were determined using the bicinchoninic acid
(BCA) protein assay kit (Pierce, Thermo Fisher Scientific Inc., Rockford, IL, USA) and enzyme activities
were expressed per mg liver protein.
2.7. Western Blot Analysis
Protein expression levels of ACC, FAS, SREBP-1c, ChREBP, and PPARα were determined by
immunoblotting as described in the Supporting Information.
2.8. Targeted Quantitative Mitochondrial Proteomics
Selected 47 mitochondrial proteins involved in substrate transport, oxidative phosphorylation,
fatty acid β-oxidation, and tricarboxylic acid (TCA) cycle were quantified in liver samples using
targeted quantitative proteomics as described in [38].
2.9. Statistical Analysis
Data are expressed as means ± standard error of the mean (SEM). The statistical significance of
differences among the diet groups was assessed using one-way analysis of variance (ANOVA) with
Tukey honest significant difference (HSD) post-hoc analyses. Differences between the two experimental
groups were determined by univariate ANOVA with Tukey HSD post-hoc analyses. Statistical analyses
were performed using IBM SPSS statistics 22 software package (SPSS, Inc.; Chicago, IL, USA). The level
of significance was set at p < 0.05.
3. Results
3.1. Caloric Sweeteners Increase Adiposity without an Effect on Body Weight
Before the start of the diets, body weights were not significantly different between groups (Table 1).
During the diet period, body weights increased similarly among the different groups (Figure 1A) and
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after 7 weeks of diet body weights were not significantly different (Table 1). However, both epididymal
and perirenal fat pads of rats in the caloric sweetener groups GLU and FRUC were increased compared
with rats in the CON and ASP groups (Table 1). Food intake was lower in the GLU and FRUC groups
compared with CON and ASP, but their drink intake was higher, resulting in a higher total energy
intake in GLU and FRUC compared with CON and ASP groups (Figure 1B, Table 1). Furthermore,
animals in the FRUC group consumed more food, but had a lower drink intake compared with GLU




Figure 1. Body weight (A) and total energy intake (B) of rats receiving normal water (CON), a 13%
(w/v) glucose solution (GLU), a 13% (w/v) fructose solution (FRUC), or a 0.4% (w/v) aspartame solution
(ASP), determined weekly (n = 15 per diet group). Data are expressed as means ± standard error of the
mean (SEM). ‡ p < 0.001 vs. GLU and FRUC; § p < 0.05, §§ p < 0.01, §§§ p < 0.001 vs. GLU.
In the FRUC group, plasma TG concentrations were higher compared with the ASP group (Table 1).
Moreover, plasma ALT levels were higher in FRUC animals compared with CON and GLU animals
(Table 1).
Liver weight and liver glycogen concentrations were analyzed separately per experimental
group (Table 1), because liver tissue was harvested under different conditions, i.e., fasted versus fed.
In both experimental groups, FRUC animals had higher liver weights compared with GLU and ASP,
while there were no significant differences in liver glycogen content between the diet groups. When
comparing between the two experimental groups, liver weight and liver glycogen content were higher
in experimental group 2 compared with experimental group 1, which is likely explained by the fasted
state of animals in experimental group 1.
3.2. Both Caloric and Non-Caloric Sweeteners Affect Whole-Body Glucose Homeostasis
Whole-body glucose tolerance was assessed with an OGTT (Table 2). There were no significant
differences in fasting plasma glucose or AUCg among the different diet groups. Fasting plasma insulin,
on the other hand, was higher in ASP and tended to be higher in GLU (p = 0.051) and FRUC (p = 0.127)
compared with CON. AUCi and the product of AUCg and AUCi also tended to be increased in GLU,
FRUC, and ASP compared with CON, although this only reached statistical significance in the case
of FRUC.
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Table 1. Animal characteristics.
CON GLU FRUC ASP
Start body weight (g) 354 ± 6 347 ± 3 351 ± 3 348 ± 3
End body weight (g) 445 ± 5 444 ± 8 456 ± 5 437 ± 6
Body weight gain (g) 92 ± 4 97 ± 6 105 ± 4 89 ± 4
Food intake (kJ/week) 2300 ± 25 1170 ± 24 ***,††† 1447 ± 36 ***,†††,§§§ 2232 ± 35
Food intake (g/week) 180 ± 2 91 ± 2 ***,††† 113 ± 3 ***,†††,§§§ 174 ± 3
Drink intake (kJ/week) NA 1757.9 ± 48.7 ††† 1274.4 ± 44.9 †††,§§§ 13.4 ± 0.5
Drink intake (mL/week) 177 ± 4 808 ± 22 ***,††† 586 ± 21 ***,†††,§§§ 201 ± 7
Total energy intake (kJ/week) 2300 ± 25 2927 ± 35 ***,††† 2721 ± 20 ***,†††,§§§ 2246 ± 36
Amount sweetener (g/kg BW/day) NA 36.87 ± 1.25 ††† 26.16 ± 1.00 †††,§§§ 0.28 ± 0.01
Epididymal fat (g) (n = 36) 5.8 ± 0.2 7.5 ± 0.4 **,†† 7.1 ± 0.3 *,† 5.6 ± 0.3
Perirenal fat (g) (n = 36) 5.8 ± 0.4 9.5 ± 0.6 ***,††† 9.0 ± 0.5 ***,††† 5.8 ± 0.4
Plasma TG (mM) 1.05 ± 0.10 1.06 ± 0.10 1.23 ± 0.04 † 0.87 ± 0.04
Plasma ALT (U/L) 24.94 ± 2.35 21.71 ± 3.11 51.21 ± 8.00 **,§§ 35.44 ± 4.32
Experimental group 1 (n = 9 per diet group)
Liver weight (g) 10.63 ± 0.14 9.97 ± 0.16 11.39 ± 0.22 †,§§ 10.17 ± 0.25
Liver glycogen (mg/g ww) 87 ± 10 78 ± 7 75 ± 4 67 ± 6
Experimental group 2 (n = 6 per diet group)
Liver weight (g) 12.92 ± 0.16 ### 13.08 ± 0.64 ### 16.25 ± 0.59 ***,†††,§§§,### 13.23 ± 0.21 ###
Liver glycogen (mg/g ww) 96 ± 3 118 ± 8 ### 117 ± 8 ### 115 ± 8 ###
Liver malonyl-CoA (nmol/g ww) 58.37 ± 0.97 62.44 ± 2.70 68.05 ± 2.32 *,†† 56.31 ± 1.82
Data are expressed as means ± standard error of the mean (SEM) of 15 animals per diet group (unless stated otherwise). Experimental group 1 was sacrificed after an overnight fast, while
experimental group 2 was sacrificed in a fed condition. CON, normal water control; GLU, 13% (w/v) glucose; FRUC, 13% (w/v) fructose; ASP, 0.4% (w/v) aspartame; NA, not applicable;
BW, body weight; TG, triglycerides; ALT, alanine aminotransferase; ww, wet weight. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. CON; † p < 0.05, †† p < 0.01, ††† p < 0.001 vs. ASP; §§ p < 0.01,
§§§ p < 0.001 vs. GLU; ### p < 0.001 vs. experimental group 1.
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Table 2. Plasma glucose and insulin concentrations during oral glucose tolerance test (OGTT).
CON GLU FRUC ASP
Fasting glucose (mM) 4.87 ± 0.21 4.44 ± 0.27 4.35 ± 0.10 5.22 ± 0.40
AUCg (mM·h) 13.67 ± 0.39 15.07 ± 0.55 14.89 ± 0.43 13.87 ± 0.46
Fasting insulin (pM) 267 ± 64 605 ± 97 500 ± 81 573 ± 61 *
AUCi (pM·h) 454 ± 64 576 ± 75 614 ± 54 562 ± 52
AUGg·AUCi (mM·h·pM·h) 5462 ± 672 8640 ± 1151 9274 ± 1031 * 7824 ± 770
Data are expressed as means ± SEM of nine animals per diet group. CON, normal water control; GLU, 13% (w/v)
glucose; FRUC, 13% (w/v) fructose; ASP, 0.4% (w/v) aspartame; AUCg, area under the glucose curve; AUCi, area
under the insulin curve. * p < 0.05 vs. CON.
3.3. Fructose Stimulates Hepatic De Novo Lipogenesis
Next, we assessed the effects of caloric and non-caloric sweeteners on hepatic lipid metabolism
in vivo using 1H-[13C] MRS (Figure 2). Figure 3 shows total IHCL content and 13C-enriched IHCL
content after the administration of [U-13C] algal lipid mixture or [U-13C6]glucose. After 7 weeks of diet,
IHCL levels were significantly higher in FRUC animals compared with CON and ASP (Figure 3A).
Four hours after the administration of [U-13C] algal lipid mixture, levels of 13C-enriched IHCL were
not significantly different among the groups, showing that dietary lipid uptake in the liver was not
significantly affected by glucose, fructose, or aspartame consumption (Figure 3B). After 5 days of
[U-13C6]glucose administration, on the other hand, 13C-enriched IHCL was significantly higher in
FRUC compared with all other groups, demonstrating increased de novo lipogenesis in the liver upon




Figure 2. (A) T1-weighted transversal image of the abdomen of a rat receiving a 13% (w/v) fructose
solution. The positioning of a 5× 2× 4 mm3 voxel in the median lobe of the liver for 1H-[13C] magnetic
resonance spectroscopy (MRS) is indicated by the white square; (B) 1H-[13C] MRS spectra from the
voxel in panel A. Spectra were acquired after 5 days of [U-13C6]glucose administration. Spectra without
13C editing, with 13C editing, and the calculated difference spectrum containing only 13C-coupled 1H
resonances (10× magnification) are shown. Peak annotations: Cho, choline; IHCL, intrahepatocellular
lipids. Total IHCL content was quantified from the spectrum without 13C editing and 13C-enriched
IHCL content was determined from the difference spectrum.
Protein expression levels of key lipogenic enzymes ACC and FAS were not affected in the ASP
group, but were increased in livers from the GLU and FRUC groups compared with the CON group,
and the effect was stronger in FRUC compared with GLU (Figure 4A,B). Furthermore, fructose but not
glucose feeding significantly increased the hepatic concentration of the ACC product malonyl-CoA
compared to the CON group (Table 1). Total hepatic protein levels of SREBP-1c were only mildly
affected in livers of GLU and FRUC animals, as indicated by a slight upregulation of SREBP-1c
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precursor compared to the CON group without an effect on cleaved SREBP-1c (Figure 4E,F). Aspartame
feeding resulted in lower protein levels of cleaved SREBP-1c compared to all other experimental groups.
Total protein levels of ChREBP were increased in response to glucose and fructose but not aspartame
feeding compared to the CON group (Figure 4D). The strongest induction was observed in the GLU
group. Upregulation of ChREBP protein levels was accompanied by increased activities of glycolytic
enzymes phosphoglucose-isomerase (Figure 5A) and, even more notably, pyruvate kinase (Figure 5C)
in livers from GLU and FRUC animals, with the strongest effects observed in the FRUC group.
The enzyme activity of phosphoglycerate kinase (Figure 5B) tended to be higher in FRUC compared
with CON (p = 0.056). The activities of glycolytic enzymes were not significantly affected by aspartame
feeding. The protein levels of PPARα were slightly decreased in GLU but not FRUC and ASP groups




Figure 3. (A) Total lipid content at baseline (n = 15 per diet group); (B) 13C-enriched IHCL 4 h after
the oral administration of [U-13C] algal lipid mixture (dietary lipid uptake; n = 9 per diet group);
and (C) 13C-enriched IHCL after 5 days of oral administration of [U-13C6]glucose (de novo lipogenesis;
n = 6 per diet group), in rats receiving normal water (CON), a 13% (w/v) glucose solution (GLU),
a 13% (w/v) fructose solution (FRUC), or a 0.4% (w/v) aspartame solution. Data are expressed as









Figure 4. Protein expression levels of (A) acetyl-CoA carboxylase (ACC); (B) fatty acid synthase
(FAS); (C) peroxisome proliferator-activated receptor α (PPARα); (D) carbohydrate-responsive
element-binding protein (ChREBP); (E) 128 kDa precursor sterol regulatory element-binding protein-1c
(SREBP-1c); and (F) 65 kDa cleaved SREBP-1c, in livers of rats receiving normal water (CON),
a 13% (w/v) glucose solution (GLU), a 13% (w/v) fructose solution (FRUC), or a 0.4% (w/v) aspartame
solution (n = 6 per diet group). All data were normalized to β-actin expression levels and are expressed
relative to the controls (CON). Data are expressed as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001




Figure 5. Glycolytic enzyme activities in liver. Activity of (A) phosphoglucose-isomerase (PGI);
(B) phosphoglycerate kinase (PGK) and (C) pyruvate kinase (PK), in livers of rats receiving normal
water (CON), a 13% (w/v) glucose solution (GLU), a 13% (w/v) fructose solution (FRUC), or a 0.4%
(w/v) aspartame solution (n = 6 per diet group). Data are expressed as means ± SEM. * p < 0.05,
*** p < 0.001 vs. CON; †† p < 0.01, ††† p < 0.001 vs. ASP; §§ p < 0.01, §§§ p < 0.001 vs. GLU.
3.4. Proteins Involved in Mitochondrial Oxidative Metabolism Are Differentially Affected by Glucose and
Fructose Feeding
To determine whether caloric and non-caloric sweeteners might influence mitochondrial fatty
acid oxidation and glucose catabolism downstream of glycolysis, i.e., via the TCA cycle, we quantified
the levels of 47 mitochondrial proteins involved in fatty acid β-oxidation, the TCA cycle, and the
oxidative phosphorylation pathway in total liver protein extracts. In agreement with the PPARα
protein expression pattern, a number of enzymes involved in mitochondrial fatty acid β-oxidation were
downregulated by glucose but not by other sweeteners. These enzymes include enoyl-CoA hydratase
(ECHS1), electron transfer flavoprotein (subunit ETFB), electron transfer flavoprotein-ubiquinone
oxidoreductase (ETFDH), and the liver isoform of carnitine palmitoyltransferase 1 (CPT1A) (Figure 6A).
The downregulation of these enzymes suggests a degree of suppression of fatty acid oxidation by
glucose. However, increased protein concentrations of trifunctional protein subunits HADHA and
HADHB may indicate a compensatory response. Fructose and aspartame largely had no effect on
protein concentrations of β-oxidation enzymes, except for downregulation of CPT1A by fructose
and trifunctional protein subunit HADHA by aspartame, and upregulation of ECHS1 by aspartame
(Figure 6A and Table A1).
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The proteomics of TCA cycle enzymes showed that both glucose and fructose caused an increase
in protein levels of two components of the acetyl-CoA producing pyruvate dehydrogenase complex,
i.e., pyruvate dehydrogenase E1 component subunit α (PDHA1) and dihydrolipoyllysine-residue
acetyltransferase (E2 component; DLAT), and the effect was more profound in the FRUC group
compared with the GLU group (Figure 6B). The protein concentration of the citrate transporter
(SLC25A1) was only affected by glucose feeding, but a number of TCA cycle enzymes downstream of
citrate were downregulated by both glucose and fructose (Figure 6B), suggesting a negative regulation
of TCA cycle activity by both sweeteners. Aspartame feeding largely had no effect on concentrations of
TCA cycle enzymes except for downregulation of 2-oxoglutarate dehydrogenase (OGDH) (Figure 6B
and Table A1).
The analysis of enzymes involved in the oxidative phosphorylation pathway showed that this
pathway was largely unaffected by the sweeteners (Table A1), except for downregulation of phosphate
carrier protein (SLC25A3) and adenine nucleotide translocase 2 (SLC25A5) (Figure 6C), indicating




Figure 6. Targeted quantitative mitochondrial proteomics of proteins involved in (A) fatty acid
β-oxidation; (B) tricarboxylic acid (TCA) cycle; and (C) oxidative phosphorylation, in livers of rats
receiving normal water (CON), a 13% (w/v) glucose solution (GLU), a 13% (w/v) fructose solution
(FRUC), or a 0.4% (w/v) aspartame solution (n = 6 per diet group). Gene names and corresponding
protein names: Cpt1a: Carnitine O-palmitoyltransferase 1A; Etfa: Electron-transfer-flavoprotein, alpha
polypeptide; Etfb: Electron-transfer-flavoprotein, beta polypeptide; Etfdh: Electron-transferring-
flavoprotein dehydrogenase; Echs1: Enoyl CoA hydratase, short chain, 1; Hadha: Hydroxyacyl-CoA
dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit;
Hadhb: Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional
protein), beta subunit; Pdha1: Pyruvate dehydrogenase E1 component subunit alpha; Dlat:
Dihydrolipoamide S-acetyltransferase; Aco2: Aconitase 2; Ogdh: Oxoglutarate (alpha-ketoglutarate)
dehydrogenase; Sucla2: Succinyl-CoA ligase [ADP-forming] subunit beta; Suclg1: Succinate-CoA ligase,
alpha subunit; Suclg2: Succinate-CoA ligase, beta subunit; Slc25a1: Solute carrier family 25, member
1; Slc25a3: Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3; Slc25a5:
Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 5. Data are expressed as
means ± SEM. * p < 0.05 vs. CON; † p < 0.05 vs. ASP; § p < 0.05 vs. GLU.
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4. Discussion
In the present study, we aimed to elucidate the effects of caloric and non-caloric sweeteners on
in vivo liver lipid metabolism in rats and to determine their roles in the development of liver steatosis.
We showed that fructose and not glucose consumption led to an increase in hepatic lipid content,
which was accompanied by an increased conversion of 13C-labeled glucose to lipids in the liver as
determined in vivo by MRS. Therefore, de novo lipogenesis appears to be an important contributor to
fructose-induced liver lipid accumulation, which was confirmed by the strongly increased expression
of lipogenic enzymes upon fructose feeding. Aspartame consumption did not significantly affect
hepatic lipid content or metabolism, while it similarly reduced whole-body glucose homeostasis
compared with glucose and fructose.
The rise in obesity and obesity-related disorders has been associated with the increased
consumption of fructose over the past decades [6,7]. In Western diets, fructose is mainly consumed
through sugar-sweetened beverages, containing 10–13% (w/v) of fructose [39]. In rat models,
the feeding of fructose both in pelleted diets and in the drinking water has been shown to lead
to hypertriglyceridemia [18,40]. However, in contrast to high-fructose pelleted diets that contain
50–70% fructose, diets incorporating 10% (w/v) of fructose in drinking water have been reported not
to modify plasma glucose or insulin concentrations [18]. In the current study, we therefore chose to
use 13% (w/v) of fructose or glucose in the drinking water, which is also better comparable with the
consumption of sugar-sweetened beverages by humans. We observed that fructose feeding resulted in
significantly elevated plasma TG concentrations when compared with aspartame feeding, whereas this
effect was not observed with glucose feeding. Plasma glucose concentrations were not significantly
affected, but plasma insulin levels tended to be increased upon the feeding of both glucose and fructose.
Therefore, effects of hyperinsulinemia on liver lipid metabolism cannot be excluded, but these effects
are expected to be similar for glucose and fructose feeding.
The animals that received the sugar-sweetened drinking water consumed up to 50% less pelleted
chow than the animals receiving normal drinking water or the aspartame solution. Nevertheless,
the total energy intake in the sugar groups was higher, due to the calories from the sugar in their
drinking water. The increased total energy intake in both sugar groups did, however, not lead to
a greater gain in body weight compared with the animals receiving normal drinking water or the
aspartame solution. This is in agreement with previous studies administering 10% fructose and/or
glucose solutions to rats [18,41–43] and may be explained by the lower dietary quality of their diets
(less protein, micronutrients, fiber, and trace elements) as a result of a lower intake of pelleted chow.
Because body weight is not always a good indicator of adiposity, especially in animals, analysis of the
body composition by determination of fat pad mass is preferred [44]. In the current study, epididymal
and perirenal fat pad weights were higher in the two sugar groups compared with the control and
aspartame groups, showing that despite the absence of a significant effect on body weight, glucose
and fructose feeding led to increased adiposity.
When comparing between the two sugar groups, the addition of glucose to the drinking water
resulted in a higher total energy intake compared with fructose, which was due to a higher consumption
of the glucose solution compared with the fructose solution. However, the consumption of pelleted
chow was higher in the fructose-fed animals compared with the glucose-fed animals. This observation
is in agreement with a previous study in rats, in which the less pronounced reduction in solid food
consumption upon fructose feeding was explained by a state of leptin resistance produced by the
ingestion of fructose [18]. However, in humans, differential effects of glucose and fructose on ad
libitum energy intake have not been observed [45].
Seven weeks of fructose administration resulted in an increased amount of lipids in the liver,
whereas the administration of glucose did not significantly affect liver lipid content compared with
normal drinking water. This observation is in accordance with previous studies comparing the effects
of glucose and fructose on liver lipid accumulation both in rodents [18,46,47] and in humans [48].
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In order to determine the cause of liver lipid accumulation upon fructose consumption, 1H-(13C)
MRS was performed combined with the oral administration of 13C-labeled lipids, to examine dietary
lipid uptake, and with the oral administration of 13C-labeled glucose, to determine de novo lipogenesis.
Chronic fructose feeding has been shown to lead to an overproduction of intestinal apoB48-containing
lipoproteins, which was associated with greater stability of intracellular apoB48 and upregulation of
the key enzyme involved in intestinal lipoprotein assembly, microsomal TG transfer protein [19–21].
Therefore, chronic fructose consumption may promote the absorption of dietary lipids from the
intestine, resulting in an increased influx of diet-derived lipids into the liver. However, 4 h after the
administration of 13C-labeled lipids, the hepatic incorporation of the ingested dietary lipids was similar
among all diet groups. Nunes et al. applied the same MRS-based method to determine dietary lipid
uptake in the livers of mice fed with pelleted diets containing 60% glucose or fructose for a period of
8 weeks [47]. Also in this study, the liver lipid pools became equally 13C enriched in the glucose- and
fructose-fed animals after the ingestion of 13C-labeled lipids, but no control group fed with normal
chow was included. It was furthermore demonstrated that plasma concentrations of apoB48 and
apoB100 were similar between the glucose- and fructose fed groups [47]. Together, these results do not
support the hypothesis that an increased influx of dietary lipids into the liver causes fructose-induced
hepatic lipid accumulation.
We then investigated the contribution of de novo lipogenesis to hepatic lipid accumulation by
administering the rats with 13C-labeled glucose for a period of 5 days, after which the conversion
of 13C-labeled glucose to 13C-labeled lipids in the liver was measured with in vivo 1H-[13C] MRS.
We showed that the 13C enrichment of the liver lipid pool upon 13C-labeled glucose administration
was 3.5-fold higher in fructose-fed animals compared with animals receiving normal drinking
water, and, moreover, that it was 2.8-fold higher in fructose-compared with glucose-fed animals.
Therefore, de novo lipogenesis appears to be an important contributor to fructose-induced liver
lipid accumulation.
The stimulation of de novo lipogenesis upon fructose feeding was further investigated by
determining the protein levels of lipogenic enzymes, ACC and FAS, and of transcription factors
involved in the transcriptional regulation of lipogenic genes, SREBP-1c and ChREBP. Glucose and
fructose feeding similarly increased the expression of ChREBP (only significantly for glucose versus
normal water) and precursor SREBP-1c in the liver, but the protein levels of mature SREBP-1c were
not elevated. However, despite the absence of a clear stimulating effect of fructose on ChREBP and
SREBP-1c with respect to glucose, the expression levels of ACC and FAS were 1.6-fold and 1.5-fold
higher in fructose- compared with glucose-fed animals, respectively. These results confirm the findings
of previous studies using sugar-sweetened drinking water [15,18,49]. A possible explanation for the
increased protein levels of ACC and FAS in fructose- compared with glucose-fed animals without
differences in ChREBP and SREBP-1c could be that the nuclear fractions of ChREBP and SREBP-1c
are responsible for inducing the expression of these lipogenic enzymes [13,14], whereas in the current
and other studies, protein levels were determined in whole liver homogenates. Janevski et al. [14]
showed that in rats fed with diets containing 60% glucose or 60% fructose, protein levels of ChREBP
and SREBP-1c were similar in liver homogenates, but were higher in the nuclear fractions from livers
of fructose-fed animals, and that this was associated with increased ACC and FAS gene transcription.
Mitochondrial proteomics provided additional proof for the fructose-induced stimulation of de
novo lipogenesis. In livers of both glucose- and fructose-fed animals, two components of the pyruvate
dehydrogenase complex were upregulated (PDHA1, DLAT), suggesting increased production of
acetyl-CoA [40]. This was in agreement with increased activities of glycolytic enzymes, in particular
pyruvate kinase, a phenomenon also reported by others [50,51]. Decreased protein levels of several TCA
cycle enzymes (ACO2, OGDH, SUCLA2, and SUCLG1), all of them catalyzing reactions downstream
of citrate, suggest that TCA cycle activity might have been limited upon glucose and fructose feeding,
favoring the translocation of citrate to the cytosol for lipogenesis [52]. Importantly, most of these effects
were more profound in response to fructose compared with glucose.
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Decreased mitochondrial fatty acid β-oxidation capacity may contribute to the accumulation
of hepatic lipids. The protein levels of transcription factor PPARα, which regulates fatty acid
catabolism, was decreased in response to glucose but not fructose feeding. However, Roglans et
al. showed that fructose feeding reduces PPARα activity without modifying hepatic PPARα protein
levels [18]. In agreement, a downregulation of CPT1A, a rate limiting enzyme in mitochondrial
β-oxidation, was observed in livers of both glucose- and fructose-fed animals, indicating decreased
mitochondrial acyl-CoA uptake and possibly β-oxidation. However, only glucose also induced
upregulation of mitochondrial trifunctional protein (subunits HADHA and HADHB), possibly
indicating a compensatory response resulting in lesser suppression of β-oxidation compared to fructose.
Furthermore, in the livers of fructose-fed animals, we observed accumulation of the CPT1A inhibitor
malonyl-CoA, leading to stronger inhibition of fatty acid β-oxidation compared to glucose [15].
The shift of fatty acids away from oxidation and towards esterification will cause an increase in
very-low density lipoprotein (VLDL) secretion, which can explain the increased plasma TG levels in
the fructose-fed animals [7,9,53,54]. However, taken together our data suggest that hepatic lipid export
was not matched to increased production and decreased oxidation.
The administration of aspartame for 7 weeks did not have a significant effect on food intake or
body weight compared with controls receiving normal drinking water. The absence of an effect on
body weight is in agreement with a study conducted by Palmnas et al., in which rats received a low
dose of aspartame in their ad libitum drinking water (5–7 mg/kg/day) for 8 weeks [31]. Those animals,
however, consumed less food and drank more fluid compared to the control animals, which was not
observed in the current study. Low dose aspartame consumption in drinking water has been shown
to increase fasting blood glucose levels and induce glucose intolerance without an effect on fasting
plasma insulin levels in both rats [31] and mice [26]. The effects were attributed to compositional
and functional changes in gut microbiota, resulting in increased production of short-chain fatty acids.
Short-chain fatty acids can serve as gluconeogenic precursors, possibly contributing to increased
hepatic glucose production and thus explaining aspartame’s negative effects on glucose tolerance. In a
recent study, however, it was shown that inhibition of the gut enzyme intestinal alkaline phosphatase
by aspartame’s breakdown product phenylalanine may explain how aspartame promotes glucose
intolerance [30]. In the present study, rats consumed a higher dose of aspartame (280 mg/kg/day)
compared to the low dose of 5–7 mg/kg/day reported in [31] and the dose of 123.3 mg/kg/day used
in [30]. In contrast to those studies, we did not observe an effect of aspartame on blood glucose levels,
but aspartame feeding led to higher fasting plasma insulin levels and trends in higher AUCi and the
product of AUCg and AUCi compared with controls. This suggests that higher doses of aspartame
may induce compensatory insulin production in the pancreas, resulting in maintenance of normal
fasting blood glucose levels and glucose disposal.
To date, the effects of aspartame on liver lipid metabolism have been largely unknown. Exploring
the impact of aspartame consumption on hepatic dietary lipid uptake and de novo lipogenesis with
1H-[13C] MRS revealed no significant effects and total liver lipid content was similar between animals
receiving aspartame or normal drinking water. The expression of most of the transcription factors
and enzymes involved in lipid metabolism was also not significantly affected by aspartame feeding,
corroborating that liver lipid metabolism is largely unaffected by aspartame. Despite of this, aspartame
feeding similarly reduced whole-body glucose homeostasis compared with glucose and fructose
feeding. In the case of glucose and especially fructose, derangements in liver lipid metabolism are
thought to contribute to the development of hepatic insulin resistance [11]. Our results indicate
that changes in liver lipid content or metabolism do not play a causative role in aspartame-induced
glucose intolerance.
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5. Conclusions
In conclusion, both glucose and fructose feeding increased adiposity, but only fructose led to
higher hepatic lipid levels. The increase in hepatic lipid content upon fructose consumption was not
caused by an increased uptake of dietary lipids into the liver, but could be attributed to an increase in
de novo lipogenesis and presumably a reduction in fatty acid β-oxidation. The non-caloric sweetener
aspartame did not significantly affect liver lipid content or metabolism, while its effects on whole-body
glucose homeostasis were comparable to glucose and fructose.
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Appendix A. Experimental Procedures
Western Blot Analysis
Powdered liver samples were homogenized in ice cold lysis buffer containing 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 150 mM NaCl, 50 mM Tris, 2 mM
NaF, 2 mM Na3VO4, protease inhibitor cocktail (1:200), pH 8. Homogenates were solubilized for
2 h at 4 ◦C and centrifuged at 14,000× g for 10 min at 4 ◦C. Equal amounts (30 µg) of total liver
protein were resolved with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to nitrocellulose membranes using Trans-Blot Turbo Midi Nitrocellulose Transfer
Packs, and Trans-Blot Turbo Transfer Starter System (Bio-Rad Laboratories Inc., Hercules, CA, USA).
After blocking with Tris-buffered saline (TBS) containing 0.1% Tween (TBST) and 5% skim milk powder
for 1 h at room temperature, the membranes were incubated overnight at 4 ◦C with antibodies against
acetyl-CoA carboxylase (ACC, 1:1000, cat. No. 3662, Cell Signaling, Danvers, MA, USA), fatty acid
synthase (FAS, 1:1000, cat. No. 3180, Cell Signaling), sterol regulatory element-binding protein-1c
(SREBP-1c) precursor and cleaved protein (1:1000, cat. No. NB600-582, Novus Biologicals, Littleton,
CO, USA), carbohydrate-responsive element-binding protein (ChREBP, 1:1000, cat. No. NB400-135,
Novus Biologicals), peroxisome proliferator-activated receptor α (PPARα, 1:1000, cat. No. sc-9000,
Santa Cruz Biotechnology), and β-actin (1:5000, cat. No. 2066, Sigma-Aldrich). Next, membranes were
washed 3 × 5 min with TBST and incubated with a corresponding horse-radish peroxidase-conjugated
secondary antibody for 1 h at room temperature. After the final wash of 3 × 5 min with TBST and
1 × 5 min with TBS, the immunocomplexes were detected using SuperSignal West Dura Extended
Duration Substrate (Pierce, Thermo Fisher Scientific Inc., Rockford, IL, USA), visualized using
ChemiDoc XRS+ imaging system, and quantified using Image Lab analysis software version 3.0
(Bio-Rad Laboratories Inc., Hercules, CA, USA). All data were normalized to β-actin protein levels and
expressed relative to the controls (CON).
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Table A1. Targeted quantitative mitochondrial proteomics in liver.
Gene Name Protein Name CON GLU FRUC ASP
Fatty acid β-oxidation
Acaa2 Acetyl-CoA acyltransferase 2 34.2 ± 0.7 32.5 ± 1.2 † 36.5 ± 2.3 39.0 ± 1.7
Acadl Acyl-CoA dehydrogenase, long-chain 38.7 ± 1.3 34.9 ± 1.6 39.0 ± 2.1 41.0 ± 1.9
Acads Acyl-CoA dehydrogenase, short-chain 11.4 ± 0.5 10.5 ± 0.2 10.9 ± 0.3 10.1 ± 0.4
Acadvl Acyl-CoA dehydrogenase, very long-chain 12.5 ± 0.6 11.5 ± 0.2 10.1 ± 0.6 * 11.0 ± 0.5
Cpt1a Carnitine O-palmitoyltransferase 1A 8.0 ± 0.2 5.7 ± 0.4 ** 5.8 ± 0.4 ** 7.0 ± 0.4
Cpt1b Carnitine O-palmitoyltransferase 1B 1.29 ± 0.07 1.96 ± 0.19 1.46 ± 0.12 1.65 ± 0.38
Cpt2 Carnitine palmitoyltransferase 2 6.2 ± 0.2 6.8 ± 0.3 6.5 ± 0.6 5.4 ± 0.3
Decr1 2,4-dienoyl CoA reductase 1 7.8 ± 0.22 7.4 ± 0.3 †† 8.3 ± 0.7 † 10.0 ± 0.2 **
Echs1 Enoyl CoA hydratase, short chain, 1 20.0 ± 0.8 16.0 ± 0.7 *,††† 18.7 ± 1.5 †† 24.1 ± 0.9 *
Eci1 Enoyl-CoA delta isomerase 11.9 ± 0.7 11.8 ± 0.7 12.0 ± 1.0 13.1 ± 0.6
Etfa Electron-transfer-flavoprotein, alpha polypeptide 18.9 ± 0.8 15.4 ± 1.0 †† 19.5 ± 1.8 23.3 ± 1.3
Etfb Electron-transfer-flavoprotein, beta polypeptide 25.1 ± 0.8 20.1 ± 1.0 **,†† 23.9 ± 1.0 25.0 ± 1.0
Etfdh Electron-transferring-flavoprotein dehydrogenase 15.5 ± 0.4 13.3 ± 0.6 ** 14.1 ± 0.4 14.6 ± 0.3
Hadh Hydroxyacyl-CoA dehydrogenase 34.4 ± 1.1 30.9 ± 1.2 32.7 ± 1.2 34.0 ± 1.2
Hadha Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase(trifunctional protein), alpha subunit 16.1 ± 0.3 18.3 ± 0.4 *
,††† 17.1 ± 0.6 ††† 13.5 ± 0.6 **
Hadhb Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase(trifunctional protein), beta subunit 13.6 ± 0.4 16.5 ± 0.3 **
,††† 15.3 ± 0.5 ††† 12.0 ± 0.4
Slc25a20 Solute carrier family 25, member 20 4.1 ± 0.2 3.1 ± 0.3 ††† 4.4 ± 0.3 § 5.4 ± 0.4 *
TCA cycle
Aco2 Aconitase 2 11.1 ± 0.4 9.9 ± 0.2 * 11.4 ± 0.1 §§,† 10.1 ± 0.3
Cs Citrate synthase 5.40 ± 0.13 4.66 ± 0.14 †† 5.59 ± 0.39 § 6.04 ± 0.09
Dlat Dihydrolipoamide S-acetyltransferase 7.1 ± 0.2 8.7 ± 0.5 *,†† 10.3 ± 0.3 ***,§§,††† 6.8 ± 0.2
Dld Dihydrolipoamide dehydrogenase 23.3 ± 0.7 21.2 ± 1.1 23.3 ± 1.1 20.7 ± 0.4
Dlst Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) 13.4 ± 0.8 11.7 ± 0.6 13.2 ± 0.2 13.3 ± 0.4
Fh1 Fumarate hydratase 1 14.1 ± 0.7 12.1 ± 0.6 15.9 ± 1.5 16.0 ± 1.0
Idh2 Isocitrate dehydrogenase 2 (NADP+) 10.0 ± 0.4 9.2 ± 0.6 9.2 ± 0.2 9.0 ± 0.3
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Table A1. Cont.
Gene Name Protein Name CON GLU FRUC ASP
Idh3a Isocitrate dehydrogenase [NAD] subunit α 3.3 ± 0.4 3.1 ± 0.5 2.7 ± 0.2 3.2 ± 0.2
Mdh2 Malate dehydrogenase 2 31.6 ± 1.0 27.2 ± 0.9 † 31.2 ± 2.0 33.8 ± 1.6
Ogdh Oxoglutarate (alpha-ketoglutarate) dehydrogenase 6.1 ± 0.1 5.3 ± 0.2 * 5.7 ± 0.2 5.3 ± 0.2 *
Pdha1 Pyruvate dehydrogenase E1 component subunit alpha 6.1 ± 0.2 7.8 ± 0.4 * 9.4 ± 0.3 ***,§,†† 7.3 ± 0.5
Pdk1 Pyruvate dehydrogenase kinase, isozyme 1 1.06 ± 0.01 1.06 ± 0.03 †† 1.17 ± 0.02 **,†† 1.05 ± 0.02
Slc25a1 Solute carrier family 25, member 1 11.8 ± 0.4 10.2 ± 0.4 * 11.7 ± 0.3 11.6 ± 0.5
Slc25a10 Solute carrier family 25, member 10 9.6 ± 0.5 6.8 ± 0.5 **,†† 8.0 ± 0.4 9.5 ± 0.6
Slc25a11 Solute carrier family 25, member 11 5.5 ± 0.4 4.6 ± 0.2 4.7 ± 0.4 5.1 ± 0.3
Slc25a22 Solute carrier family 25, member 22 3.99 ± 0.11 3.31 ± 0.09 **,† 3.22 ± 0.11 **,†† 3.85 ± 0.15
Sucla2 Succinyl-CoA ligase [ADP-forming] subunit beta 8.2 ± 0.3 6.5 ± 0.2 ***,†† 6.9 ± 0.2 ** 7.8 ± 0.3
Suclg1 Succinate-CoA ligase, alpha subunit 18.9 ± 0.6 15.2 ± 0.5 **,† 16.3 ± 0.7 * 18.5 ± 0.7
Suclg2 Succinate-CoA ligase, beta subunit 11.6 ± 0.3 10.3 ± 0.3 †† 10.9 ± 0.2 † 12.7 ± 0.6
Oxidative phosphorylation
Ndufs1 NADH dehydrogenase (ubiquinone) Fe-S protein 1 5.4 ± 0.3 4.5 ± 0.2 * 5.8 ± 0.2 §§ 5.1 ± 0.2
Sdha Succinate dehydrogenase complex, subunit A, flavoprotein 10.0 ± 0.3 8.9 ± 0.3 * 9.7 ± 0.2 9.9 ± 0.3
Sdhb Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 6.8 ± 0.2 5.1 ± 0.1 *,††† 6.9 ± 0.5 §§ 7.4 ± 0.3
Uqcrc2 Ubiquinol-cytochrome c reductase core protein II 8.5 ± 0.3 7.3 ± 0.3 ††† 9.1 ± 0.5 § 9.9 ± 0.4
Cox5a Cytochrome c oxidase subunit Va 5.31 ± 0.24 4.86 ± 0.23 †† 5.70 ± 0.08 § 5.79 ± 0.11
Cycs Cytochrome c, somatic 3.26 ± 0.25 2.94 ± 0.14 2.88 ± 0.09 3.13 ± 0.13
Atp5b ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 63.2 ± 2.1 58.4 ± 2.5 † 71.5 ± 5.2 § 73.0 ± 2.1
Slc25a3 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 22.4 ± 0.7 17.2 ± 0.5 *** 19.3 ± 0.9 * 19.0 ± 0.8 *
Slc25a4 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 4 0.97 ± 0.04 0.87 ± 0.05 0.86 ± 0.02 0.83 ± 0.03
Slc25a5 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 5 49.4 ± 1.7 39.8 ± 1.3 ** 43.6 ± 1.9 42.7 ± 1.1 *
Ucp2 Uncoupling protein 2 0.80 ± 0.04 0.84 ± 0.06 0.70 ± 0.04 0.71 ± 0.06
Ucp3 Uncoupling protein 3 0.92 ± 0.04 1.08 ± 0.12 † 0.81 ± 0.04 0.78 ± 0.05
Data are expressed as means ± SEM of six animals per diet group. CON, normal water control; GLU, 13% (w/v) glucose; FRUC, 13% (w/v) fructose; ASP, 0.4% (w/v) aspartame. * p < 0.05,
** p < 0.01, *** p < 0.001 vs. CON; † p < 0.05, †† p < 0.01, ††† p < 0.001 vs. ASP; § p < 0.05, §§ p < 0.01 vs. GLU.
Nutrients 2017, 9, 476 17 of 19
References
1. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.;
Abbafati, C.; Abera, S.F.; et al. Global, regional, and national prevalence of overweight and obesity in
children and adults during 1980–2013: A systematic analysis for the global burden of disease study 2013.
Lancet 2014, 384, 766–781. [CrossRef]
2. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221–1231. [CrossRef] [PubMed]
3. Berlanga, A.; Guiu-Jurado, E.; Porras, J.A.; Auguet, T. Molecular pathways in non-alcoholic fatty liver disease.
Clin. Exp. Gastroenterol. 2014, 7, 221–239. [PubMed]
4. Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: Old questions and new insights. Science
2011, 332, 1519–1523. [CrossRef] [PubMed]
5. Bray, G.A.; Nielsen, S.J.; Popkin, B.M. Consumption of high-fructose corn syrup in beverages may play a
role in the epidemic of obesity. Am. J. Clin. Nutr. 2004, 79, 537–543. [PubMed]
6. Bray, G.A. Soft drink consumption and obesity: It is all about fructose. Curr. Opin. Lipidol. 2010, 21, 51–57.
[CrossRef] [PubMed]
7. Stanhope, K.L.; Schwarz, J.M.; Keim, N.L.; Griffen, S.C.; Bremer, A.A.; Graham, J.L.; Hatcher, B.; Cox, C.L.;
Dyachenko, A.; Zhang, W.; et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases
visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Investig.
2009, 119, 1322–1334. [CrossRef] [PubMed]
8. Neuschwander-Tetri, B.A. Carbohydrate intake and nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr.
Metab. Care 2013, 16, 446–452. [CrossRef] [PubMed]
9. Tappy, L.; Le, K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010, 90,
23–46. [CrossRef] [PubMed]
10. Softic, S.; Cohen, D.E.; Kahn, C.R. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver
disease. Dig. Dis. Sci. 2016, 61, 1282–1293. [CrossRef] [PubMed]
11. Samuel, V.T. Fructose induced lipogenesis: From sugar to fat to insulin resistance. Trends Endocrinol. Metab.
2011, 22, 60–65. [CrossRef] [PubMed]
12. Stanhope, K.L.; Schwarz, J.M.; Havel, P.J. Adverse metabolic effects of dietary fructose: Results from the
recent epidemiological, clinical, and mechanistic studies. Curr. Opin. Lipidol. 2013, 24, 198–206. [CrossRef]
[PubMed]
13. Koo, H.Y.; Miyashita, M.; Cho, B.H.; Nakamura, M.T. Replacing dietary glucose with fructose increases
ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem. Biophys. Res. Commun. 2009, 390, 285–289.
[CrossRef] [PubMed]
14. Janevski, M.; Ratnayake, S.; Siljanovski, S.; McGlynn, M.A.; Cameron-Smith, D.; Lewandowski, P. Fructose
containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription
factors ChREBP and SREBP1c with no effect on body weight or liver fat. Food Funct. 2012, 3, 141–149.
[CrossRef] [PubMed]
15. Rebollo, A.; Roglans, N.; Baena, M.; Sanchez, R.M.; Merlos, M.; Alegret, M.; Laguna, J.C. Liquid fructose
downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver
cells. Biochim. Biophys. Acta 2014, 1841, 514–524. [CrossRef] [PubMed]
16. Liu, L.; Yang, M.; Lin, X.; Li, Y.; Liu, C.; Yang, Y.; Yamahara, J.; Wang, J. Modulation of hepatic sterol
regulatory element-binding protein-1c-mediated gene expression contributes to Salacia oblonga root-elicited
improvement of fructose-induced fatty liver in rats. J. Ethnopharmacol. 2013, 150, 1045–1052. [CrossRef]
[PubMed]
17. Rizkalla, S.W. Health implications of fructose consumption: A review of recent data. Nutr. Metab. Lond. 2010,
7, 82. [CrossRef] [PubMed]
18. Roglans, N.; Vila, L.; Farre, M.; Alegret, M.; Sanchez, R.M.; Vazquez-Carrera, M.; Laguna, J.C. Impairment of
hepatic Stat-3 activation and reduction of PPARα activity in fructose-fed rats. Hepatology 2007, 45, 778–788.
[CrossRef] [PubMed]
19. Parks, E.J.; Krauss, R.M.; Christiansen, M.P.; Neese, R.A.; Hellerstein, M.K. Effects of a low-fat,
high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J. Clin. Investig. 1999,
104, 1087–1096. [CrossRef] [PubMed]
Nutrients 2017, 9, 476 18 of 19
20. Haidari, M.; Leung, N.; Mahbub, F.; Uffelman, K.D.; Kohen-Avramoglu, R.; Lewis, G.F.; Adeli, K. Fasting and
postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance.
Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo
lipogenesis and Apob48-containing lipoprotein overproduction. J. Biol. Chem. 2002, 277, 31646–31655.
[PubMed]
21. Lewis, G.F.; Uffelman, K.; Naples, M.; Szeto, L.; Haidari, M.; Adeli, K. Intestinal lipoprotein overproduction,
a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone:
Studies in the fructose-fed Syrian golden hamster. Endocrinology 2005, 146, 247–255. [CrossRef] [PubMed]
22. Chattopadhyay, S.; Raychaudhuri, U.; Chakraborty, R. Artificial sweeteners—A review. J. Food Sci. Technol.
2014, 51, 611–621. [CrossRef] [PubMed]
23. Mitsutomi, K.; Masaki, T.; Shimasaki, T.; Gotoh, K.; Chiba, S.; Kakuma, T.; Shibata, H. Effects of a nonnutritive
sweetener on body adiposity and energy metabolism in mice with diet-induced obesity. Metabolism 2014, 63,
69–78. [CrossRef] [PubMed]
24. Anton, S.D.; Martin, C.K.; Han, H.; Coulon, S.; Cefalu, W.T.; Geiselman, P.; Williamson, D.A. Effects of stevia,
aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. Appetite 2010,
55, 37–43. [CrossRef] [PubMed]
25. Raben, A.; Vasilaras, T.H.; Moller, A.C.; Astrup, A. Sucrose compared with artificial sweeteners: Different
effects on ad libitum food intake and body weight after 10 weeks of supplementation in overweight subjects.
Am. J. Clin. Nutr. 2002, 76, 721–729. [PubMed]
26. Suez, J.; Korem, T.; Zeevi, D.; Zilberman-Schapira, G.; Thaiss, C.A.; Maza, O.; Israeli, D.; Zmora, N.; Gilad, S.;
Weinberger, A.; et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature
2014, 514, 181–186. [CrossRef] [PubMed]
27. Bellisle, F.; Drewnowski, A. Intense sweeteners, energy intake and the control of body weight. Eur. J.
Clin. Nutr. 2007, 61, 691–700. [CrossRef] [PubMed]
28. Davidson, T.L.; Martin, A.A.; Clark, K.; Swithers, S.E. Intake of high-intensity sweeteners alters the ability of
sweet taste to signal caloric consequences: Implications for the learned control of energy and body weight
regulation. Q. J. Exp. Psychol. Hove 2011, 64, 1430–1441. [CrossRef] [PubMed]
29. Swithers, S.E. Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements.
Trends Endocrinol. Metab. 2013, 24, 431–441. [CrossRef] [PubMed]
30. Gul, S.S.; Hamilton, A.R.L.; Munoz, A.R.; Phupitakphol, T.; Liu, W.; Hyoju, S.K.; Economopoulos, K.P.;
Morrison, S.; Hu, D.; Zhang, W.F.; et al. Inhibition of the gut enzyme intestinal alkaline phosphatase may
explain how aspartame promotes glucose intolerance and obesity in mice. Appl. Physiol. Nutr. Metab. 2017,
42, 77–83. [CrossRef] [PubMed]
31. Palmnas, M.S.; Cowan, T.E.; Bomhof, M.R.; Su, J.; Reimer, R.A.; Vogel, H.J.; Hittel, D.S.; Shearer, J. Low-dose
aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced
obese rat. PLoS ONE 2014, 9, e109841. [CrossRef] [PubMed]
32. Jonkers, R.A.; Geraedts, T.R.; van Loon, L.J.; Nicolay, K.; Prompers, J.J. Multitissue assessment of in vivo
postprandial intracellular lipid partitioning in rats using localized 1H-[13C] magnetic resonance spectroscopy.
Magn. Reson. Med. 2012, 68, 997–1006. [CrossRef] [PubMed]
33. Jonkers, R.A.; van Loon, L.J.; Nicolay, K.; Prompers, J.J. In vivo postprandial lipid partitioning in liver and
skeletal muscle in prediabetic and diabetic rats. Diabetologia 2013, 56, 618–626. [CrossRef] [PubMed]
34. Demoz, A.; Garras, A.; Asiedu, D.K.; Netteland, B.; Berge, R.K. Rapid method for the separation and detection
of tissue short-chain coenzyme a esters by reversed-phase high-performance liquid chromatography.
J. Chromatogr. B Biomed. Appl. 1995, 667, 148–152. [CrossRef]
35. Van Hoek, P.; Flikweert, M.T.; van der Aart, Q.J.; Steensma, H.Y.; van Dijken, J.P.; Pronk, J.T. Effects of
pyruvate decarboxylase overproduction on flux distribution at the pyruvate branch point in saccharomyces
cerevisiae. Appl. Environ. Microbiol. 1998, 64, 2133–2140. [PubMed]
36. Van Hoek, P.; van Dijken, J.P.; Pronk, J.T. Regulation of fermentative capacity and levels of glycolytic enzymes
in chemostat cultures of saccharomyces cerevisiae. Enzym. Microb. Technol. 2000, 26, 724–736. [CrossRef]
37. Van Hoek, P.; Van Dijken, J.P.; Pronk, J.T. Effect of specific growth rate on fermentative capacity of baker’s
yeast. Appl. Environ. Microbiol. 1998, 64, 4226–4233. [PubMed]
Nutrients 2017, 9, 476 19 of 19
38. Wolters, J.C.; Ciapaite, J.; van Eunen, K.; Niezen-Koning, K.E.; Matton, A.; Porte, R.J.; Horvatovich, P.;
Bakker, B.M.; Bischoff, R.; Permentier, H.P. Translational targeted proteomics profiling of mitochondrial
energy metabolic pathways in mouse and human samples. J. Proteome Res. 2016, 15, 3204–3213. [CrossRef]
[PubMed]
39. Ventura, E.E.; Davis, J.N.; Goran, M.I. Sugar content of popular sweetened beverages based on objective
laboratory analysis: Focus on fructose content. Obesity 2011, 19, 868–874. [CrossRef] [PubMed]
40. Park, O.J.; Cesar, D.; Faix, D.; Wu, K.; Shackleton, C.H.; Hellerstein, M.K. Mechanisms of fructose-induced
hypertriglyceridaemia in the rat. Activation of hepatic pyruvate dehydrogenase through inhibition of
pyruvate dehydrogenase kinase. Biochem. J. 1992, 282, 753–757. [CrossRef] [PubMed]
41. Peredo, H.A.; Lee, H.; Donoso, A.S.; Andrade, V.; Sanchez Eluchans, N.; Puyo, A.M. A high-fat plus fructose
diet produces a vascular prostanoid alterations in the rat. Auton. Autacoid Pharmacol. 2015, 34, 35–40.
[CrossRef] [PubMed]
42. Castro, M.C.; Francini, F.; Gagliardino, J.J.; Massa, M.L. Lipoic acid prevents fructose-induced changes
in liver carbohydrate metabolism: Role of oxidative stress. Biochim. Biophys. Acta 2014, 1840, 1145–1151.
[CrossRef] [PubMed]
43. Sheludiakova, A.; Rooney, K.; Boakes, R.A. Metabolic and behavioural effects of sucrose and fructose/glucose
drinks in the rat. Eur. J. Nutr. 2012, 51, 445–454. [CrossRef] [PubMed]
44. Thibault, L.; Woods, S.C.; Westerterp-Plantenga, M.S. The utility of animal models of human energy
homeostasis. Br. J. Nutr. 2004, 92, S41–S45. [CrossRef] [PubMed]
45. Kuzma, J.N.; Cromer, G.; Hagman, D.K.; Breymeyer, K.L.; Roth, C.L.; Foster-Schubert, K.E.; Holte, S.E.;
Callahan, H.S.; Weigle, D.S.; Kratz, M. No difference in ad libitum energy intake in healthy men and women
consuming beverages sweetened with fructose, glucose, or high-fructose corn syrup: A randomized trial.
Am. J. Clin. Nutr. 2015, 102, 1373–1380. [CrossRef] [PubMed]
46. Koo, H.Y.; Wallig, M.A.; Chung, B.H.; Nara, T.Y.; Cho, B.H.; Nakamura, M.T. Dietary fructose induces a
wide range of genes with distinct shift in carbohydrate and lipid metabolism in fed and fasted rat liver.
Biochim. Biophys. Acta 2008, 1782, 341–348. [CrossRef] [PubMed]
47. Nunes, P.M.; Wright, A.J.; Veltien, A.; van Asten, J.J.; Tack, C.J.; Jones, J.G.; Heerschap, A. Dietary lipids do
not contribute to the higher hepatic triglyceride levels of fructose-compared to glucose-fed mice. FASEB J.
2014, 28, 1988–1997. [CrossRef] [PubMed]
48. Lecoultre, V.; Egli, L.; Carrel, G.; Theytaz, F.; Kreis, R.; Schneiter, P.; Boss, A.; Zwygart, K.; Le, K.A.;
Bortolotti, M.; et al. Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic
lipids in healthy humans. Obesity 2013, 21, 782–785. [CrossRef] [PubMed]
49. Vila, L.; Roglans, N.; Perna, V.; Sanchez, R.M.; Vazquez-Carrera, M.; Alegret, M.; Laguna, J.C. Liver
AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose
intolerance in rats ingesting liquid fructose. J. Nutr. Biochem. 2011, 22, 741–751. [CrossRef] [PubMed]
50. Hagopian, K.; Chen, Y.; Simmons Domer, K.; Soo Hoo, R.; Bentley, T.; McDonald, R.B.; Ramsey, J.J. Caloric
restriction influences hydrogen peroxide generation in mitochondrial sub-populations from mouse liver.
J. Bioenerg. Biomembr. 2011, 43, 227–236. [CrossRef] [PubMed]
51. Dukhande, V.V.; Sharma, G.C.; Lai, J.C.; Farahani, R. Chronic hypoxia-induced alterations of key enzymes of
glucose oxidative metabolism in developing mouse liver are mTOR dependent. Mol. Cell. Biochem. 2011, 357,
189–197. [CrossRef] [PubMed]
52. Liao, C.C.; Lin, Y.L.; Kuo, C.F. Effect of high-fat diet on hepatic proteomics of hamsters. J. Agric. Food Chem.
2015, 63, 1869–1881. [CrossRef] [PubMed]
53. Roberts, R.; Bickerton, A.S.; Fielding, B.A.; Blaak, E.E.; Wagenmakers, A.J.; Chong, M.F.; Gilbert, M.; Karpe, F.;
Frayn, K.N. Reduced oxidation of dietary fat after a short term high-carbohydrate diet. Am. J. Clin. Nutr.
2008, 87, 824–831. [PubMed]
54. Chong, M.F.; Fielding, B.A.; Frayn, K.N. Mechanisms for the acute effect of fructose on postprandial lipemia.
Am. J. Clin. Nutr. 2007, 85, 1511–1520. [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
